Author

R. G. Majzner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 4 Approach:experimental assay· 3 Approach:genetic perturbation / CRISPR· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

C. L. Mackall· 4 shared E. Sotillo· 4 shared P. Xu· 4 shared A. T. Satpathy· 3 shared A. Banuelos· 2 shared A. Delaidelli· 2 shared E. W. Weber· 2 shared H. Y. Chang· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

C. L. Mackall

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Engineered CD47 protects T cells for enhanced antitumor immunity

S. A. Yamada-Hunter, J. Theruvath, B. J. McIntosh, K. A. Freitas, M. T. Radosevich, A. Leruste, S. Dhingra, N. Martinez-Velez, P. Xu, A. Delaidelli, M. H. Desai, Z. Good, L. Labanieh, C. W. Mount, Y. Chen, , C. L. Mackall

This paper engineers a CD47 variant to protect T cells from macrophage clearance, enhancing antitumor efficacy by combining T cell and macrophage activation.

bioRxiv · Jun 20, 2023 · PreprintBioengineering

Enhanced Effector Activity of Mediator Kinase Module Deficient CAR-T Cells

K. A. Freitas, J. A. Belk, E. Sotillo, B. Daniel, K. Sandor, D. Klysz, V. T. Duong, K. A. Burdsall, P. Xu, M. Malipatlolla, M. G. Donovan, E. W. Weber, R. G. Majzner, H. Y. Chang, J. M. Espinosa, , C. L. Mackall

This study identifies the Mediator kinase module as a regulator of T cell differentiation and shows that its inhibition enhances effector T cell potency.

bioRxiv · Sep 2, 2022 · PreprintImmunology

Latent human herpesvirus 6 is reactivated in chimeric antigen receptor T cells

C. A. Lareau, Y. Yin, K. Maurer, K. D. Sandor, G. Yagnik, J. Pena, J. C. Crawford, A. M. Spanjaart, J. C. Gutierrez, N. J. Haradvala, T. Abay, R. R. Stickels, J. M. Verboon, V. Liu, J. Southard, , A. T. Satpathy

The paper identifies HHV-6 reactivation in CAR T cells using single-cell sequencing and links it to clinical neurotoxicity observed in patients.

bioRxiv · Aug 12, 2022 · PreprintImmunology

Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication

J. Theruvath, M. Menard, B. A. Smith, M. H. Linde, G. Coles, W. Wu, L. Kiru, A. Delaidelli, J. L. Silberstein, A. Banuelos, S. Dhingra, E. Sotillo, S. Heitzeneder, A. Tousley, J. Lattin, , R. G. Majzner

This study shows that combining anti-GD2 and anti-CD47 antibodies enhances anti-tumor responses by recruiting macrophages and disrupting the GD2:Siglec-7 interaction in GD2+ cancers.

bioRxiv · Mar 19, 2021 · PreprintImmunology

Transient "rest" induces functional reinvigoration and epigenetic remodeling in exhausted CAR-T cells

E. W. Weber, R. C. Lynn, K. R. Parker, H. Anbunathan, J. Lattin, E. Sotillo, Z. Good, M. Malipatlolla, P. Xu, P. Vandris, R. G. Majzner, Y. Qi, L.-C. Chen, A. J. Gentles, T. J. Wandless, , C. L. Mackall

This study shows that temporarily stopping CAR-T cell signaling can reverse exhaustion and improve their anti-tumor function through transcriptional and epigenetic changes.

bioRxiv · Jan 26, 2020 · PreprintImmunology